Rate of misclassification in patients undergoing radical prostatectomy but fulfilling active surveillance criteria according to the European Association of Urology guidelines on prostate cancer: a high-volume center experience

被引:6
作者
Hoeffkes, Friis [1 ]
Arthanareeswaran, Vinodh-Kumar-Adithyaa [1 ]
Stolzenburg, Jens-Uwe [1 ]
Ganzer, Roman [2 ]
机构
[1] Univ Leipzig, Dept Urol, Leipzig, Germany
[2] Asklepios Hosp, Dept Urol, Bad Tolz, Germany
关键词
Prostatectomy; Guideline; Prostatic neoplasms; EPSTEIN CRITERIA; PATHOLOGICAL OUTCOMES; CANDIDATES; MEN; MORTALITY; SELECTION; BIOPSY;
D O I
10.23736/S0393-2249.18.03126-0
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: The aim of the study was to identify the rate of pathologic upgrading and upstaging in a cohort of patients diagnosed with prostate cancer (PCa) who met inclusion criteria for active surveillance (AS) by the European Association of Urology (EAU) guidelines on prostate cancer but decided to undergo radical prostatectomy (RPE). Our goal was to determine possible predictive parameters that may be associated with unfavorable disease. METHODS: Single center retrospective analysis of patients who underwent RPE despite qualifying for AS according to the EAU AS criteria (defined as PSA <= 10 ng/mL, biopsy Gleason Score < 7, clinical stage <= T2a, <= 2 positive biopsy cores and <= 50% cancer involvement of every positive core). Based on the final histopathology report we evaluated the rates of Gleason Score upgrading and upstaging to non-organ confined disease. Multivariate logistic regression analysis was performed to identify preoperative parameters that may correlate with disease upgrading and upstaging. RESULTS: Among 2345 patients, who underwent RPE between March 2007 and October 2013, 372 were included in our study. Final pathology report revealed Gleason Score upgrading in 105 (28.2%) patients and an extraprostatic extension (upstaging >= pT3a) in 24 (6.4%) patients. There was no preoperative parameter that correlated statistically significantly with unfavorable disease. CONCLUSIONS: Our results indicate that the current criteria for AS cannot reliably differentiate between clinically significant or insignificant PCa and therefore offer limited utility in patient selection. Inclusion of more reliable tools like mpMRI novel biological markers might contribute to refine the current AS criteria.
引用
收藏
页码:588 / 593
页数:6
相关论文
共 29 条
[1]   Mortality Results from a Randomized Prostate-Cancer Screening Trial [J].
Andriole, Gerald L. ;
Grubb, Robert L., III ;
Buys, Saundra S. ;
Chia, David ;
Church, Timothy R. ;
Fouad, Mona N. ;
Gelmann, Edward P. ;
Kvale, Paul A. ;
Reding, Douglas J. ;
Weissfeld, Joel L. ;
Yokochi, Lance A. ;
Crawford, E. David ;
O'Brien, Barbara ;
Clapp, Jonathan D. ;
Rathmell, Joshua M. ;
Riley, Thomas L. ;
Hayes, Richard B. ;
Kramer, Barnett S. ;
Izmirlian, Grant ;
Miller, Anthony B. ;
Pinsky, Paul F. ;
Prorok, Philip C. ;
Gohagan, John K. ;
Berg, Christine D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (13) :1310-1319
[2]   Phase 3 Study of Adjuvant Radiotherapy Versus Wait and See in pT3 Prostate Cancer: Impact of Pathology Review on Analysis [J].
Bottke, Dirk ;
Golz, Reinhard ;
Stoerkel, Stephan ;
Hinke, Axel ;
Siegmann, Alessandra ;
Hertle, Lothar ;
Miller, Kurt ;
Hinkelbein, Wolfgang ;
Wiegel, Thomas .
EUROPEAN UROLOGY, 2013, 64 (02) :193-198
[3]   The Value of Mandatory Second Opinion Pathology Review of Prostate Needle Biopsy Interpretation Before Radical Prostatectomy [J].
Brimo, Fadi ;
Schultz, Luciana ;
Epstein, Jonathan I. .
JOURNAL OF UROLOGY, 2010, 184 (01) :126-130
[4]   Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study [J].
Bul, Meelan ;
Zhu, Xiaoye ;
Valdagni, Riccardo ;
Pickles, Tom ;
Kakehi, Yoshiyuki ;
Rannikko, Antti ;
Bjartell, Anders ;
van der Schoot, Deric K. ;
Cornel, Erik B. ;
Conti, Giario N. ;
Boeve, Egbert R. ;
Staerman, Frederic ;
Vis-Maters, Jenneke J. ;
Vergunst, Henk ;
Jaspars, Joris J. ;
Stroelin, Petra ;
van Muilekom, Erik ;
Schroder, Fritz H. ;
Bangma, Chris H. ;
Roobol, Monique J. .
EUROPEAN UROLOGY, 2013, 63 (04) :597-603
[5]   Contemporary trends in low risk prostate cancer: Risk assessment and treatment [J].
Cooperberg, Matthew R. ;
Broering, Jeannette M. ;
Kantoff, Philip W. ;
Carroll, Peter R. .
JOURNAL OF UROLOGY, 2007, 178 (03) :S14-S19
[6]   Active Surveillance for Prostate Cancer: A Systematic Review of the Literature [J].
Dall'Era, Marc A. ;
Albertsen, Peter C. ;
Bangma, Christopher ;
Carroll, Peter R. ;
Carter, H. Ballentine ;
Cooperberg, Matthew R. ;
Freedland, Stephen J. ;
Klotz, Laurence H. ;
Parker, Christopher ;
Soloway, Mark S. .
EUROPEAN UROLOGY, 2012, 62 (06) :976-983
[7]   A Multi-institutional Evaluation of Active Surveillance for Low Risk Prostate Cancer [J].
Eggener, Scott E. ;
Mueller, Alex ;
Berglund, Ryan K. ;
Ayyathurai, Raj ;
Soloway, Cindy ;
Soloway, Mark S. ;
Abouassaly, Robert ;
Klein, Eric A. ;
Jones, Steven J. ;
Zappavigna, Chris ;
Goldenberg, Larry ;
Scardino, Peter T. ;
Eastham, James A. ;
Guillonneau, Bertrand .
JOURNAL OF UROLOGY, 2009, 181 (04) :1635-1641
[8]  
Gaudreau Pierre-Olivier, 2016, Biomark Cancer, V8, P15, DOI 10.4137/BIC.S31802
[9]  
Grasso AAC, 2016, MINERVA UROL NEFROL, V68, P237
[10]   Magnetic resonance imaging on disease reclassification among active surveillance candidates with low-risk prostate cancer: a diagnostic meta-analysis [J].
Guo, R. ;
Cai, L. ;
Fan, Y. ;
Jin, J. ;
Zhou, L. ;
Zhang, K. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2015, 18 (03) :221-228